bioMérieux SA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: FR0013280286
EUR
107.10
-44.05 (-29.14%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About bioMérieux SA stock-summary
stock-summary
bioMérieux SA
Pharmaceuticals & Biotechnology
Biomerieux SA is a France-based company that specializes in the field of in-vitro diagnostics for medical and industrial applications. The Company designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial applications, such as for the analysis of industrial or environmental samples. The Company also provides its customers with related services for the installation and maintenance of instruments, and training for product users. BioMerieux SA operates through its numerous subsidiaries in various countires, including bioMerieux Deutschland GmbH, bioMerieux Austria GmbH, Advencis, bioMerieux Benelux SA/NV, as well as BioFire Diagnostics Inc., chromID CARBA SMART and new bi-plate Petri dish.
Company Coordinates stock-summary
Company Details
376 chemin de l'Orme , MARCY-L ETOILE None : 69280
stock-summary
Tel: 33 4 7887200033 4 78872237
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 2 Foreign Institutions (0.01%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Alexandre Merieux
Chairman of the Board, Chairman of the Executive Committee, Chief Executive Officer, Non-Independent Director
Mr. Philippe Archinard
Non-Independent Director
Mr. Jean-Luc Belingard
Non-Independent Director
Mr. Harold Boel
Independent Director
Ms. Marie-Helene Habert-Dassault
Independent Director
Ms. Marie-Paule Kieny
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 12,748 Million ()

stock-summary
P/E

27.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.00

stock-summary
Return on Equity

12.50%

stock-summary
Price to Book

3.24